Determination of two HMG-CoA reductase inhibitors, pravastatin and pitavastatin, in plasma samples using liquid chromatography-tandem mass spectrometry for pharmaceutical study

Biomedical Chromatography

Volumn 22, Issue 2, 2008, Pages 131-135

  Deng, Jian Wei ^a   Kim, Kwon Bok ^a   Song, Im Sook ^a   Shon, Ji Hong ^a,b   Zhou, Hong Hao ^c   Liu, Kwang Hyeon ^a,d   Shin, Jae Gook ^a,b  

^a Inje University College of Medicine   (South Korea)

^b Inje University College of Medicine   (South Korea)

^c CENTRAL SOUTH UNIVERSITY   (China)

^d Inje University   (South Korea)

Author keywords

HMG CoA; LC MS MS; Pitavastatin; Pravastatin

Indexed keywords

DRUG PRODUCTS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY;

3-HYDROXY-3-METHYLGLUTARYL COENZYME A; COENZYME A; FLUVASTATIN; LC-MS-MS; LC.MS/MS; ORAL DOSE; PITAVASTATIN; PLASMA SAMPLES; PRAVASTATIN; REDUCTASE INHIBITORS;

PHASE SEPARATION;

ACETONITRILE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHANOL; PITAVASTATIN; PRAVASTATIN; WATER;

ACCURACY; ANALYTIC METHOD; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STRUCTURE; ELUTION; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; NORMAL HUMAN; SENSITIVITY ANALYSIS; SINGLE DRUG DOSE; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY;

EID: 39349083148     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.905     Document Type: Article

References (23)

1. Bauer S, Mwinyi J, Stoeckle A, Gerloff T and Roots I. Quantification of pravastatin in human plasma and urine after solid phase extraction using high performance liquid chromatography with ultraviolet detection. Journal of chromatography 2005; 818: 257-262.
2. Chung JY, Cho JY, Yu KS, Kim JR, Oh DS, Jung HR, Lim KS, Moon KH, Shin SG and Jang IJ. Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clinical Pharmacology and Therapeutics 2005; 78: 342-350.
3. Fujino H, Saito T, Tsunenari Y and Kojima J. Effect of gemfibrozil on the metabolism of pitavastatin - determining the best animal model for human CYP and UGT activities. Drug Metabolism and Drug Interactions 2004; 20: 25-42.
4. Hatanaka T. Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events. Clinical Pharmacokinetics 2000; 39 397-412.
5. Hirano M, Maeda K, Shitara Y and Sugiyama Y. Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metabolism and Disposition: the Biological Fate of Chemicals 2006; 34: 1229-1236.
6. Kawabata K, Samata N and Urasaki Y. Quantitative determination of pravastatin and R-416, its main metabolite in human plasma, by liquid chromatography-tandem mass spectrometry. Journal of Chromatography 2005; 816: 73-79.
7. Kojima J, Fujino H, Yosimura M, Morikawa H and Kimata H. Simultaneous determination of NK-104 and its lactone in biological samples by column-switching high-performance liquid chromatography with ultraviolet detection. Journal of Chromatography B: Biomedical Science Applications 1999; 724: 173-180.
8. Lennernas H. Clinical pharmacokinetics of atorvastatin. Clinical Pharmacokinetics 2003; 42: 1141-1160.
9. Maeda K, Ieiri I, Yasuda K, Fujino A, Fujiwara H, Otsubo K, Hirano M, Watanabe T, Kitamura Y, Kusuhara H and Sugiyama Y. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clinical Pharmacology and Therapeutics 2006; 79: 427-439.
10. Miao XS and Metcalfe CD. Determination of cholesterol-lowering statin drugs inaqueous samples using liquid chromatography-electrospray ionization tandem mass spectrometry. Journal of Chromatography A 2003: 998: 133-141.
11. Muck W. Clinical pharmacokinetics of cerivastatin. Clinical Pharmacokinetics 2000; 39: 99-116.
12. Mukhtar RY, Reid J and Reckless JP. Pitavastatin. International Journal of Clinical Practice 2005; 59: 239-252.
13. Mulvana D, Jemal M and Pulver SC. Quantitative determination of pravastatin and its biotransformation products in human serum by turbo ion spray LC/MS/MS. Journal of Pharmaceutical and Biomedical Analysis 2000; 23: 851-866.
14. Niemi M, Schaeffeler E, Lang T, Fromm MF, Neuvonen M, Kyrklund C, Backman JT, Kerb R, Schwab M, Neuvonen PJ, Eichelbaum M and Kivisto KT. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 2004; 14: 429-440.
15. Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T, Takane H, Irie S, Kusuhara H, Urasaki Y, Urae A, Higuchi S, Otsubo K and Sugiyama Y. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clinical Pharmacology and Therapeutics 2003; 73: 554-565.
16. Pasha MK, Muzeeb S, Basha SJ, Shashikumar D, Mullangi R and Srinivas NR. Analysis of five HMG-CoA reductase inhibitor - atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. Biomedical Chromatography 2006; 20: 282-293.
17. Prueksaritanont T, Gorham LM, Ma B, Liu L, Yu X, Zhao JJ, Slaughter DE, Arison BH and Vyas KP. In vitro metabolism of simvastatin in humans [SBT]: identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metabolism and Disposition: the Biological Fate of Chemicals 1997; 25: 1191-1199.
18. Reid IR, Hague W, Emberson J, Baker J, Tonkin A, Hunt D, MacMahon S and Sharpe N. Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term intervention with pravastatin in ischaemic disease. Lancet 2001; 357: 509-512.
19. Stewart RA, Sharples KJ, North FM, Menkes DB, Baker J and Simes J. Long-term assessment of psychological well-being in a randomized placebo-controlled trial of cholesterol reduction with pravastatin. The LIPID Study Investigators. Archives of Internal Medicine 2000; 160: 3144-3152.
20. Transon C, Leemann T, Vogt N and Dayer P. In vivo inhibition profile of cytochrome P45OTB (CYP2C9) by (+/-)-fluvastatin. Clinical Pharmacology and Therapeutics 1995; 58: 412-417.
21. Transon C, Leemann T and Dayer P. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. European Journal of Clinical Pharmacology 1996; 50: 209-215.
22. Wang RW, Kari PH, Lu AY, Thomas PE, Guengerich FP and Vyas KP. Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. Archives of Biochemistry and Biophysics 1991; 290: 355-361.
23. Zhu Z and Neirinck L. High-performance liquid chromatography coupled with negative ion tandem mass spectrometry for determination of pravastatin in human plasma. Journal of Chromatography 2003; 83: 133-140.